VRTX Vertex Pharmaceuticals Incorporated Stock Quote

VRTX [NASD]

Index	S&P 500	P/E	23.85	EPS (ttm)	7.59	Insider Own	0.10%	Shs Outstand	258.99M	Perf Week	-2.45%
Market Cap	47.86B	Forward P/E	13.75	EPS next Y	13.16	Insider Trans	7.85%	Shs Float	258.85M	Perf Month	-0.36%
Income	1.99B	PEG	2.45	EPS next Q	3.08	Inst Own	92.00%	Short Float	1.71%	Perf Quarter	-9.70%
Sales	6.68B	P/S	7.16	EPS this Y	128.00%	Inst Trans	0.34%	Short Ratio	2.70	Perf Half Y	-14.59%
Book/sh	35.51	P/B	5.10	EPS next Y	6.27%	ROA	16.80%	Target Price	258.45	Perf Year	-14.73%
Cash/sh	25.36	P/C	7.13	EPS next 5Y	9.75%	ROE	22.80%	52W Range	176.36 - 242.99	Perf YTD	-23.44%
Dividend	-	P/FCF	26.92	EPS past 5Y	45.30%	ROI	26.40%	52W High	-25.54%	Beta	0.62
Dividend %	-	Quick Ratio	4.40	Sales past 5Y	43.20%	Gross Margin	87.90%	52W Low	2.60%	ATR	3.32
Employees	3400	Current Ratio	4.60	Sales Q/Q	17.60%	Oper. Margin	33.90%	RSI (14)	42.79	Volatility	1.97% 1.79%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-91.90%	Profit Margin	29.80%	Rel Volume	0.73	Prev Close	180.94
Shortable	Yes	LT Debt/Eq	0.06	Earnings	Nov 02 AMC	Payout	0.00%	Avg Volume	1.65M	Price	180.94
Recom	2.00	SMA20	-0.39%	SMA50	-3.61%	SMA200	-11.53%	Volume	0	Change	0.00%

Sep-09-21

Downgrade

Stifel

Buy → Hold

$244 → $213

Sep-07-21

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$202

Jul-20-21

Downgrade

SVB Leerink

Mkt Perform → Underperform

$170

Jul-19-21

Resumed

Wolfe Research

Outperform

$252

Jul-01-21

Initiated

Raymond James

Mkt Perform

Jun-11-21

Downgrade

Daiwa Securities

Outperform → Neutral

$210

Feb-23-21

Upgrade

Robert W. Baird

Neutral → Outperform

$220 → $252

Feb-02-21

Reiterated

H.C. Wainwright

Buy

$315 → $275

Dec-30-20

Initiated

Daiwa Securities

Outperform

$250

Nov-30-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$247 → $267

Nov-20-20

Initiated

Bernstein

Outperform

$225

Oct-28-20

Initiated

UBS

Buy

$287

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$295 → $315

Jul-08-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$300

Apr-30-20

Reiterated

H.C. Wainwright

Buy

$270 → $295

Apr-28-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$250 → $260

Mar-04-20

Initiated

Barclays

Overweight

$271

Jan-31-20

Downgrade

Robert W. Baird

Outperform → Neutral

$210 → $230

Nov-19-19

Upgrade

Guggenheim

Neutral → Buy

$252

Nov-12-19

Initiated

SunTrust

Buy

$235

Oct-28-21 07:01AM	How Big Is Vertex's News for Its Potential Diabetes Cure? Motley Fool
Oct-27-21 12:07PM	Vertex's Supplement to a New Drug Submission for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada CNW Group
11:15AM	Recovery in Drugs Sales to Aid AbbVie's (ABBV) Q3 Earnings Zacks
10:14AM	Stocks sold for tax reasons often surge at year-end: Bank of America Yahoo Finance
09:25AM	Vertex (VRTX) to Report Q3 Earnings: What's in the Cards? Zacks
08:36AM	IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards? Zacks
07:25AM	10 Healthcare and Software Stocks to Buy According to Michel Massouds Melqart Asset Management Insider Monkey
Oct-26-21 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
03:03PM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
09:21AM	In defining moment, spinout from Nobel Prize winner Jennifer Doudna's lab inks gene therapy deal American City Business Journals
09:00AM	Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases Business Wire
Oct-25-21 11:06AM	CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-22-21 08:00AM	Vertex to Announce Third-Quarter 2021 Financial Results on November 2 Business Wire
07:05AM	Biotech Buyouts That Would Be Great for Investors Motley Fool
05:55AM	3 of the Best Stocks to Buy Now With $500 Motley Fool
Oct-21-21 11:04AM	Can Vertex (VRTX) Climb 42% to Reach the Level Wall Street Analysts Expect? Zacks
Oct-20-21 05:45PM	Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know Zacks
01:23PM	4 Healthcare Stocks Selling for Way Less Than Analysts Think Theyre Worth Barrons.com
06:00AM	Why Are Investors Ignoring Vertex's Good News? Motley Fool
Oct-19-21 11:30AM	If You Invested $5,000 in Vertex Pharmaceuticals In 2016, This Is How Much You Would Have Today Motley Fool
11:08AM	Vertex's (VRTX) Early Type I Diabetes Study Data Promising Zacks
10:00AM	Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Value Stock Zacks
08:58AM	10 Healthcare Stocks to Buy According to Billionaire Noam Gottesmans GLG Partners Insider Monkey
08:50AM	Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener Zacks
08:00AM	Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC) Business Wire
Oct-18-21 05:46PM	Vertex Unveils First Patient Results On Potential Diabetes Treatment Benzinga
07:30AM	Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes Business Wire
05:51AM	3 No-Brainer Stocks to Invest $500 In Right Now Motley Fool
Oct-17-21 09:01AM	2 Stocks You'll Probably Never Want to Sell Motley Fool
Oct-16-21 06:04AM	3 No-Brainer Biotech Stocks to Buy Right Now Motley Fool
Oct-15-21 02:12PM	10 Pharmaceutical Stocks to Buy According to Lawrence Hawkins Prosight Capital Insider Monkey
05:55AM	3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More Motley Fool
Oct-13-21 05:45PM	Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Zacks
12:10PM	Why the Earnings Surprise Streak Could Continue for Vertex (VRTX) Zacks
07:15AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade Motley Fool
06:00AM	3 Top Healthcare Stocks That Could Rise More Than 40% in 12 Months Motley Fool
Oct-12-21 02:18PM	Bullish insiders bet US$8.2m on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Simply Wall St.
11:40AM	VRTX vs. PRTA: Which Stock Should Value Investors Buy Now? Zacks
Oct-11-21 11:11AM	J&J (JNJ) Seeks Stelara Label Expansion in Juvenile Arthritis Zacks
10:17AM	Boston Scientific (BSX) Reports Data Backing Eluvia Stent Zacks
Oct-09-21 10:15AM	2 Beaten-Down Growth Stocks to Buy Hand Over Fist Motley Fool
Oct-08-21 05:52AM	3 Unstoppable Stocks to Buy in October Motley Fool
Oct-07-21 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
10:23AM	Voyager (VYGR) Surges on Gene Therapy Deal With Pfizer Zacks
06:00AM	3 Top Healthcare Stocks to Buy for October Motley Fool
Oct-06-21 09:00AM	Boston Biotech Star Vertex Struggles to Reprise Its One Big Hit Bloomberg
Oct-05-21 11:00AM	Abbott (ABT) Gets FDA Nod for Amplatzer Talisman System Zacks
Oct-04-21 05:53PM	Here's Why You Should Retain Myriad Genetics (MYGN) for Now Zacks
10:56AM	Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth Zacks
Oct-03-21 06:55AM	3 Stocks to Buy Without Any Hesitation If There's an October Stock Market Crash Motley Fool
Sep-30-21 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Moves -0.46%: What You Should Know Zacks
11:30AM	2 Healthcare Stocks You Can Buy and Hold for the Next Decade Motley Fool
06:17AM	3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better Motley Fool
06:05AM	3 Winning Biotech Stocks to Buy Hand Over Fist Motley Fool
05:51AM	4 Stocks Expected to Increase Sales 25,750% to 2,970,000% in 5 Years Motley Fool
Sep-29-21 11:33AM	Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study Zacks
Sep-28-21 11:45AM	FDA Accepts Bristol Myers (BMY) sBLAs for Opdivo Combo for ESCC Zacks
09:13AM	Hedge Funds Arent Crazy About Vertex Pharmaceuticals Incorporated (VRTX) Anymore Insider Monkey
05:55AM	3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30% Motley Fool
05:51AM	Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter Motley Fool
Sep-27-21 01:24PM	Should You Now Consider Selling Your Vertex Pharmaceuticals (VRTX) Stake? Insider Monkey
Sep-25-21 06:20AM	September Sell-Off Alert: Buy Vertex Pharmaceuticals on the Dip Motley Fool
Sep-24-21 08:53AM	The Zacks Analyst Blog Highlights: Disney, Adobe, Wells Fargo, IHS Markit and Vertex Pharma Zacks
06:48AM	Zacks Value Investor Highlights: Nu Skin Enterprises, VF Corp, Yamana Gold, Meritor and Vertex Pharmaceuticals Zacks
Sep-23-21 05:45PM	Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know Zacks
01:54PM	5 Top Ranked Stocks on Sale Right Now Zacks
01:23PM	Is Vertex Pharmaceuticals (VRTX) A Smart Long-Term Buy? Insider Monkey
11:40AM	VRTX vs. PRTA: Which Stock Should Value Investors Buy Now? Zacks
08:03AM	4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace Zacks
Sep-22-21 02:30PM	5 Stocks to Buy in the September Sell-Off Motley Fool
11:16AM	Vertex's Supplement to a New Drug Submission for KALYDECO® (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada CNW Group
Sep-21-21 09:34AM	Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug Zacks
06:45AM	Is Now the Time to Ditch Pharma Stocks? Motley Fool
Sep-19-21 06:06AM	3 Winning Stocks Down 33% (or More) to Buy Hand Over Fist Motley Fool
Sep-17-21 05:45PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know Zacks
04:19PM	Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA®(elexacaftor/tezacaftor/ivacaftor and ivacaftor) CNW Group
Sep-16-21 09:38AM	Here's Why You Should Retain QIAGEN (QGEN) Stock For Now Zacks
Sep-15-21 11:36AM	5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now Zacks
10:53AM	Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence Zacks
10:26AM	Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance Zacks
Sep-14-21 09:05AM	3 Crash-Ready Stocks to Buy in September Motley Fool
05:51AM	3 Nasdaq 100 Stocks Begging to Be Bought in September Motley Fool
Sep-13-21 08:00AM	Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th Business Wire
Sep-11-21 11:45AM	2 Top Biotech Stocks to Buy Right Now Motley Fool
05:55AM	2 Biotech Stocks That Are Better Buys Than Moderna Motley Fool
Sep-10-21 05:45PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know Zacks
09:15AM	Vertex Pharmaceuticals Is in a Long-Term Decline TheStreet.com
06:30AM	3 Top Healthcare Stocks to Buy for September Motley Fool
Sep-09-21 12:00PM	What Makes Vertex (VRTX) a New Strong Buy Stock Zacks
10:10AM	Perrigo (PRGO) to Acquire Another Self-Care Company HRA Pharma Zacks
Sep-07-21 05:00PM	3 Healthcare Stocks That Might Skyrocket When COVID Is Over Motley Fool
04:19PM	Insiders Are Buying Biotech Stocks Again TheStreet.com
11:09AM	Bayer's (BAYRY) Chronic Cough Candidate Meets Efficacy Goal Zacks
Sep-04-21 07:55AM	Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics Motley Fool
05:51AM	3 Stocks to Buy Hand Over Fist if There's a Stock Market Crash Motley Fool
Sep-03-21 09:44AM	Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults Zacks
Sep-02-21 10:26AM	3 Large Biotech Stocks Worth Adding to Your Portfolio Zacks
10:15AM	2 of the Best Stocks to Buy Right Now with Just $500 Motley Fool
Aug-31-21 01:25PM	15 Best Pharmaceutical Stocks to Invest In Insider Monkey
Aug-27-21 07:49AM	Despite Recent Underperformance, Institutions are Liking Vertex Pharmaceuticals (NASDAQ:VRTX) Simply Wall St.

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kewalramani Reshma	CEO & President	Aug 19	Buy	195.65	10,000	1,956,492	73,754	Aug 23 08:30 AM
SACHS BRUCE I	Director	Aug 02	Buy	197.91	15,000	2,968,650	41,210	Aug 04 04:05 PM
Bhatia Sangeeta N.	Director	Jun 02	Sale	209.69	559	117,216	5,191	Jun 04 04:03 PM
Arbuckle Stuart A	EVP, Chief Comm & Ops Officer	May 17	Sale	216.41	109	23,589	41,103	May 19 04:04 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 17	Sale	216.36	79	17,093	33,589	May 19 04:02 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 17	Sale	216.34	112	24,230	34,108	May 19 04:10 PM
Sachdev Amit	EVP, Chief Patient Officer	May 17	Sale	216.35	45	9,736	40,133	May 19 04:08 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 03	Sale	218.43	960	209,691	34,108	May 05 09:23 PM
Sachdev Amit	EVP, Chief Patient Officer	Apr 27	Option Exercise	86.52	3,884	336,044	44,017	Apr 29 04:03 PM
Sachdev Amit	EVP, Chief Patient Officer	Apr 27	Sale	216.06	3,884	839,193	40,133	Apr 29 04:03 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Apr 05	Sale	214.14	1,686	361,046	35,834	Apr 07 04:04 PM
Liu Joy	SVP, General Counsel	Mar 05	Sale	209.69	5,141	1,078,018	8,253	Mar 08 04:10 PM
Silva Paul M	SVP & Chief Accounting Officer	Mar 01	Sale	211.45	2,782	588,255	9,884	Mar 02 04:07 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 25	Sale	213.47	1,080	230,551	14,884	Feb 26 04:23 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 25	Sale	213.42	3,586	765,307	40,133	Feb 26 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 25	Sale	213.38	3,028	646,125	30,837	Feb 26 04:18 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 25	Sale	213.54	3,634	775,989	41,103	Feb 26 04:07 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 25	Sale	213.39	3,028	646,139	33,589	Feb 26 04:03 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 18	Sale	211.83	4,295	909,828	16,828	Feb 19 04:21 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 18	Sale	211.83	9,264	1,962,366	46,665	Feb 19 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 18	Sale	211.83	7,825	1,657,556	36,281	Feb 19 04:18 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 18	Sale	211.82	7,825	1,657,481	47,635	Feb 19 04:08 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 18	Sale	211.83	7,825	1,657,590	39,033	Feb 19 04:05 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 11	Sale	210.55	4,460	939,068	63,542	Feb 16 04:20 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 11	Sale	210.57	1,498	315,437	23,863	Feb 16 04:24 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Feb 11	Sale	210.56	1,686	355,012	38,864	Feb 16 04:22 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 11	Sale	210.56	4,318	909,179	50,346	Feb 16 04:15 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 11	Sale	210.55	5,156	1,085,593	61,700	Feb 16 04:07 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 11	Sale	210.54	5,283	1,112,274	53,098	Feb 16 04:02 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Option Exercise	86.52	1,930	166,984	59,157	Feb 09 07:44 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Sale	215.00	1,930	414,950	57,227	Feb 09 07:44 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Option Exercise	86.52	1,554	134,452	71,511	Feb 05 04:43 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Option Exercise	86.52	400	34,608	57,627	Feb 05 04:52 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Sale	216.56	400	86,624	57,227	Feb 05 04:52 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Sale	213.74	1,554	332,146	69,957	Feb 05 04:43 PM
Sachdev Amit	EVP, Chief Patient Officer	Nov 16	Sale	223.53	42	9,388	35,103	Nov 18 04:16 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 16	Sale	223.53	91	20,341	26,838	Nov 18 04:12 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 16	Sale	223.64	7	1,565	35,179	Nov 18 04:11 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 16	Sale	223.47	38	8,492	28,902	Nov 18 04:10 PM
SACHS BRUCE I	Director	Nov 10	Buy	217.36	15,000	3,260,465	26,210	Nov 12 08:18 AM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Option Exercise	86.52	2,330	201,592	29,168	Nov 06 04:09 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Sale	217.74	2,330	507,329	26,838	Nov 06 04:09 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Option Exercise	86.52	1,553	134,366	36,732	Nov 05 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Sale	211.92	1,553	329,115	35,179	Nov 05 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience